KISSIMMEE, Fla., Feb. 26 -- A test that tallies the number of androgen receptors in a single prostate cancer cell may be an effective predictor of disease metastasis, said researchers here.
The test, which relies on quantitative immunofluorescence to measure androgen receptors and other molecular markers, demonstrated a sensitivity of 84% and specificity of 75% for predicting clinical progression in five years of definitive surgery, said Michael Donovan, M.D., Ph.D., of Aureon Laboratories in Yonkers, N.Y., which developed the assay.
Dr. Donovan said his results were based on androgen receptor analyses conducted on prostate cancer tissue from 758 men who had a radical prostatectomy at Memorial Sloan-Kettering Cancer Center from 1985 through 2003. He reported the findings at a prostate cancer symposium.
http://www.medpagetoday.com/MeetingCoverage/ASCOProstate/tb1/5141
No comments:
Post a Comment